NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72162-2208-06 | 72162-2208 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 5, 2024 | In Use | ||
72162-2209-03 | 72162-2209 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 5, 2024 | In Use | ||
82868-0026-30 | 82868-0026 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 9, 2023 | In Use | ||
82868-0038-30 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 5, 2024 | In Use | ||
82868-0038-90 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 18, 2024 | In Use | ||
83634-0203-74 | 83634-0203 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Feb. 28, 2024 | In Use | ||
57377-0025-01 | 57377-0025 | Estradiol pellet | Estra-25 | 25.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
57377-0050-01 | 57377-0050 | Estradiol pellet | Estra-50 | 50.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
68001-0610-25 | 68001-0610 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Feb. 28, 2024 | In Use | ||
76075-0101-01 | 76075-0101 | Carfilzomib | Kyprolis | 60.0 mg/30mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | July 20, 2012 | In Use | |
76075-0102-01 | 76075-0102 | Carfilzomib | Kyprolis | 30.0 mg/15mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | July 15, 2016 | In Use | |
76075-0103-01 | 76075-0103 | carfilzomib | KYPROLIS | 10.0 mg/5mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | May 23, 2018 | In Use | |
63020-0078-01 | 63020-0078 | Ixazomib | Ninlaro | 2.3 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | No Longer Used | |
63020-0078-02 | 63020-0078 | Ixazomib | Ninlaro | 2.3 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0079-01 | 63020-0079 | Ixazomib | Ninlaro | 3.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | No Longer Used | |
63020-0079-02 | 63020-0079 | Ixazomib | Ninlaro | 3.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0080-01 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0080-02 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0049-01 | 63020-0049 | Bortezomib | Velcade | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 13, 2003 | In Use | |
00409-1703-01 | 00409-1703 | BORTEZOMIB | BORTEZOMIB | 2.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 16, 2022 | In Use | |
00409-1704-01 | 00409-1704 | BORTEZOMIB | BORTEZOMIB | 1.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 16, 2022 | In Use | |
10019-0991-01 | 10019-0991 | Bortezomib | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
25021-0244-10 | 25021-0244 | BORTEZOMIB | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
51817-0586-01 | 51817-0586 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use |
Found 10,000 results in 5 milliseconds — Export these results